Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Status:
Not yet recruiting
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
Subjects with biopsy-proven NASH will be randomly assigned in a 2:1 ratio to oral doses of
namodenoson 25 mg every 12 hours or matching placebo every 12 hours for 36 weeks. Subjects
will be evaluated regularly for safety, and efficacy biomarkers will be measured at Baseline
and Weeks 6, 12, 24, and 36. At Week 36, all subjects will undergo liver biopsy.